MR-Guided Transurethral Ultrasound Ablation (TULSA)-An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer.

Fiche publication

Date publication

mars 2024

Journal

Cardiovascular and interventional radiology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr GANGI Afshin , Pr LANG Hervé , Dr GARNON Julien , Dr TRICARD Thibault , Dr CAZZATO Roberto-Luigi

Tous les auteurs :
Fung KFK, Cazzato RL, Tricard T, Marini PDE, Bertucci G, Autrusseau PA, Koch G, Weiss J, Garnon J, Lang H, Gangi A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38491163

Résumé

The optimal treatment strategy for men with localised prostatic cancer of low and intermediate risk is an actively evolving field. It is important to strike a balance between maximal oncological control and minimal treatment-related complications, which helps preserve the patients' quality of life. MR-guided transurethral ultrasound ablation (TULSA) has emerged as a minimally invasive treatment option for this group of patients. This article aims to provide of a background on TULSA technology, a step-by-step procedural guide of MR-guided TULSA and to summarise the current evidence of TULSA in management of localised prostatic cancer, as well as other potential indications.